PhilogenS.p.A., a privately-owned biotechnology company, announce that the Swiss national competent authority Swissmedic issued the authorization to run a clinical phase II study in patients with locally advanced, not metastatic nonmelanoma skin cancer. A favourable opinion about the study has now also been obtained by EKOS (Ethics Committee of Eastern Switzerland).Nidlegy, the combination of the two active principles bifikafuspalfa (L19IL2) and onfekafuspalfa (L19TNF), has already shown promising results in the intralesional neoadjuvant treatment of patients with resectable Stage III melanoma in two phase III clinical trials.Patients enrolled in the clinical study will be treated with intralesional injections of Nidlegy. The durable responses, the excellent safety profile and the favourable cosmetic outcome of injected melanoma lesions have reinforced the investigation of efficacy and safety of Nidlegy in injectable, locally advanced and not metastatic lesions of basal cell carcinoma or cutaneous squamous cell carcinoma."We are delighted to start the clinical phase II study in Switzerland and to explore the potential of Nidlegy in patients with locally advanced, not metastatic nonmelanoma skin cancer," commented Prof. Dario Neri, co-founder and president of the Scientific Advisory Board of Philogen.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!